BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 28582730)

  • 1. RITA plus 3-MA overcomes chemoresistance of head and neck cancer cells via dual inhibition of autophagy and antioxidant systems.
    Shin D; Kim EH; Lee J; Roh JL
    Redox Biol; 2017 Oct; 13():219-227. PubMed ID: 28582730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis.
    Roh JL; Kim EH; Jang H; Shin D
    Redox Biol; 2017 Apr; 11():254-262. PubMed ID: 28012440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer.
    Shin D; Kim EH; Lee J; Roh JL
    Free Radic Biol Med; 2018 Dec; 129():454-462. PubMed ID: 30339884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
    Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
    Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Nrf2 with wogonin overcomes cisplatin resistance in head and neck cancer.
    Kim EH; Jang H; Shin D; Baek SH; Roh JL
    Apoptosis; 2016 Nov; 21(11):1265-1278. PubMed ID: 27544755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of the Glutathione, Thioredoxin, and Nrf2 Antioxidant Systems in Head and Neck Cancer.
    Roh JL; Jang H; Kim EH; Shin D
    Antioxid Redox Signal; 2017 Jul; 27(2):106-114. PubMed ID: 27733046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hederagenin Induces Apoptosis in Cisplatin-Resistant Head and Neck Cancer Cells by Inhibiting the Nrf2-ARE Antioxidant Pathway.
    Kim EH; Baek S; Shin D; Lee J; Roh JL
    Oxid Med Cell Longev; 2017; 2017():5498908. PubMed ID: 29456786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Polyphenol Conjugate Sensitizes Cisplatin-Resistant Head and Neck Cancer Cells to Cisplatin via Nrf2 Inhibition.
    Kim EH; Jang H; Roh JL
    Mol Cancer Ther; 2016 Nov; 15(11):2620-2629. PubMed ID: 27550943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.
    Roh JL; Park JY; Kim EH; Jang HJ; Kwon M
    Cancer Lett; 2016 Feb; 371(1):20-9. PubMed ID: 26607904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
    Roh JL; Park JY; Kim EH
    Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
    Roh JL; Kim EH; Jang H; Shin D
    Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance.
    Bu Y; Cai G; Shen Y; Huang C; Zeng X; Cao Y; Cai C; Wang Y; Huang D; Liao DF; Cao D
    Cancer Lett; 2016 Dec; 383(2):261-271. PubMed ID: 27721021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin.
    Roh JL; Kim EH; Park JY; Kim JW
    Mol Cancer Ther; 2015 Aug; 14(8):1907-15. PubMed ID: 26063766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
    Kim EH; Shin D; Lee J; Jung AR; Roh JL
    Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
    Roh JL; Park JY; Kim EH; Jang HJ
    Eur J Cancer; 2016 Jan; 52():163-72. PubMed ID: 26687835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isodeoxyelephantopin induces protective autophagy in lung cancer cells via Nrf2-p62-keap1 feedback loop.
    Wang Y; Zhang J; Huang ZH; Huang XH; Zheng WB; Yin XF; Li YL; Li B; He QY
    Cell Death Dis; 2017 Jun; 8(6):e2876. PubMed ID: 28617433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p62/SQSTM1 protects against cisplatin-induced oxidative stress in kidneys by mediating the cross talk between autophagy and the Keap1-Nrf2 signalling pathway.
    Liao W; Wang Z; Fu Z; Ma H; Jiang M; Xu A; Zhang W
    Free Radic Res; 2019 Jul; 53(7):800-814. PubMed ID: 31223046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling.
    Xu T; Yang Y; Chen Z; Wang J; Wang X; Zheng Y; Wang C; Wang Y; Zhu Z; Ding X; Zhou J; Li G; Zhang H; Zhang W; Wu Y; Song X
    J Exp Clin Cancer Res; 2023 Aug; 42(1):190. PubMed ID: 37525222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.
    Bao LJ; Jaramillo MC; Zhang ZB; Zheng YX; Yao M; Zhang DD; Yi XF
    Int J Clin Exp Pathol; 2014; 7(4):1502-13. PubMed ID: 24817946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.